Zotide Injection contains Teriparatide 750 mcg, a recombinant form of parathyroid hormone used primarily in the treatment of osteoporosis. Teriparatide acts by stimulating new bone formation, increasing bone mineral density, and improving bone strength, thereby reducing the risk of fractures in patients with severe osteoporosis or those at high risk of fracture. It is indicated for postmenopausal women, men with osteoporosis, and individuals with glucocorticoid-induced osteoporosis who have a history of fractures or are at significant risk. Administered via subcutaneous injection, Zotide Injection is typically prescribed as a daily dose, with treatment duration generally limited to 24 months due to safety considerations. Common adverse effects may include nausea, dizziness, leg cramps, and injection site reactions. It is contraindicated in patients with hypercalcemia, bone malignancies, or metabolic bone diseases other than osteoporosis. Careful monitoring of serum calcium levels is recommended during therapy. Zotide Injection should be used under strict medical supervision, with consideration of patient-specific risk factors and concurrent medications. This therapy offers a valuable option for patients requiring anabolic treatment to restore bone mass and reduce fracture incidence in osteoporosis management.